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Type 1 Diabetes Mellites (T1DM), is an autoimmune disorder caused by the 
destruction of pancreatic b-cells and is considered to be among the most prevalent 
chronic conditions in Qatar. This study aimed to identify the differential methylation 
status in pediatric T1DM subjects from the population of Qatar. Also, to explore the 
correlation between nutritional factors and gut microbial composition and its 
metabolites with DNA methylation. In this study, we recruited a total of 72 subjects 
that were divided into four groups (T1DM = 35, T1DM-OB = 9, obese = 16, and healthy 
= 12). Different measurements were collected from the study subjects, which are 24-
hour dietary recall, physical and biochemical data along with blood samples. 
Nutritionist Pro software (Axxya Inc) was used for the determination of the micro-and 
macro-nutrients intake for each study subject. CpG DNA methylation level was 
measured by Illumina Infinium EPIC Array and analysis of the generated data was 
conducted through the use of  GenomeStudio. Differential methylated genes were 
identified using ParteK Genomic Suite software and then analyzed using Ingenuity 
Pathway Analysis (IPA) for functional pathway analysis. Network analysis was 
performed to identify the potential correlation of  DNA methylation with dietary 
factors, gut microbiome, and SCFAs was explored in pediatric T1DM subjects. Based 
on the dietary analysis, the T1DM group was found to have a lower intake of SFA and 
vitamin K compared to healthy and obese groups. DNA methylation analysis showed 
the up-regulation of the SAPCD1 gene in T1DM patients and the down-regulation of 




The significant canonical pathways identified to be downregulated in T1DM-OB are 
aldosterone signaling in epithelial cells, xenobiotic metabolism CAR/PXR pathways 
and NRF2 mediated oxidative stress response. Furthermore, T1DM patients were found 
to have low gut microbial abundance compared to healthy controls . Our network 
analysis, showed a positive correlation of DNA methylation level with folate and 
thiamin intake in healthy controls. We have also identified a positive correlation 
between the microbial genus Lachnospira with DNA methylation in obese subjects.     
In this study, we were able to shed the light on the possible interaction between dietary 
components, DNA methylation and gut microbiome in T1DM development in children. 
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Chapter 1: Introduction 
 
Type 1 diabetes mellitus (T1DM) is an auto-immune inflammatory disorder that 
destroys pancreatic b-cells and  leads to insulin deficiency. T1DM patients are at a high 
risk of developing chronic and acute complications due to impaired glucose metabolism 
(hyperglycemia or hypoglycemia) [1]. The pathophysiology behind T1DM 
development is complex and involves the interaction between genetics, environment, 
and the immune system [2, 3]. Various genetic loci are associated with the disease 
susceptibility, mainly the human leucocyte antigens-DR/DQ (HLA-DR/DQ) locus [4]. 
Moreover, different environmental factors, such as infection, diet, early nutrition, mode 
of delivery, antibiotic use, and psychological stress are implicated in the onset and 
progression of T1DM [5]. Obesity has been long known as a concurrent phenotype 
observed with T2DM, but its association and development in T1DM cases are still 
under investigation. A study conducted between 2010 - 2012 found that overweight and 
obesity account for 22.9% and 13.1%, respectively in T1DM adolescents [6]. Several 
epigenetic modifications, mainly DNA methylation, histone modification, and micro-
RNA (miRNA) are found to have an essential role in the development of several 
autoimmune disorders including T1DM [7]. DNA methylation is found to be involved 
in the pathophysiology behind T1DM development as it alters the expression of certain 
genes involved in insulin secretion, b-cell survival and autoimmunity [7]. A genome-
wide DNA methylation study generated from T1DM discordant monozygotic twins 
identified 132 T1DM–associated methylation variable positions mostly in genes 
involved in apoptosis, inflammation, and the immune system [8]. Although T1DM 
patients are found to have unique DNA methylation patterns compared to healthy 




clearly understood. Several studies conducted in other metabolic disorders, such as 
obesity and Type 2 Diabetes mullites (T2DM) have found that the interaction between 
gut microbiome and immunity acts through epigenetic mechanisms [10]. However, it 
is not clear yet whether such mechanism is relevant for T1DM development as well. 
The development of obesity seen in T1DM patients may be attributed to different 
factors, including epigenetics, nutrition and gut microbiome [11]. However, such 
association is yet to be confirmed.  
Hypothesis  
We hypothesize that T1DM patients have a unique methylation status, and it 
plays an important role in the onset and progression of the disease. External factors, 
such as different dietary habits, BMI, and gut microbiome composition, can affect the 
DNA methylation contributing to explain the pathogenesis of T1DM and its high 
incidence seen in the young Qatari population.  
Aim and Objectives  
The  study aimed  to identify any differential methylation status in T1DM patients 
compared to T1DM obese, not diabetic obese, and lean healthy subjects. The study 
objectives were  the following: 
•   To measure the levels of DNA methylation on blood samples from T1DM patients, 
T1DM obese, obese, and lean healthy controls, using the Illumina Infinium EPIC 
Array 
•   To identify differentially methylated signatures in T1DM patients compared to 
T1DM obese, obese, and lean healthy controls. 




•   To correlate the DNA methylation levels with the gut microbiome (data previously 
measured). 
Study Design  
 This study aimed  to determine the influence of DNA methylation on T1DM 
development and to link its effect with nutrient intake and gut microbiome composition. 
The target subjects were T1DM children compared to T1DM obese (T1DM-OB), obese 
and healthy lean participants. Different physical and biochemical tests were performed 
along with the 24-hours dietary recall. Blood samples were obtained from each subject 
for the DNA methylation analysis using the Illumina Epic Array. Differentially 
methylated genes were identified using Partek software and canonical and disease 
pathway analysis was conducted using Ingenuity pathway analysis (IPA) to define the 
affected pathways. Gut microbiome and microbial metabolite analysis were available 
from previous analyses and correlated with the methylation data. Finally, an integration 
analysis was applied to show the effect of diet and gut microbiome on DNA methylation 





















Chapter 2: Literature Review 
2.1 Background   
Diabetes mellitus (DM) is a group of metabolic disorders characterized by 
impaired glucose control and the development of hyperglycemia. The classic symptoms 
associated with DM are polyuria, polydipsia, susceptibility to infection, and fatigue 
[12]. Based on the American Diabetes Association (ADA), diabetes is classified into 
four main types, which are T1DM, T2DM, gestational diabetes mellitus (GDM), and 
diabetes due to other causes [13]. T1DM is a chronic disease caused by the autoimmune 
destruction of pancreatic b-cells and insulin deficiency. The presence of T1DM 
associated auto-antibodies and HLA susceptibility variants are considered important 
risk factors in T1DM development and progression [4]. T1DM patients have a higher 
risk of developing co-morbidities, such as cardiovascular disorders (myocardial 
infarction and stroke), retinopathy, neuropathy, and nephropathy [14]. 
According to the International Diabetes Federation (IDF), T1DM incidence is 
increasing, with approximately one million cases present annually [17]. In the US, the 
prevalence of T1DM disease among adolescence (< 20 years old) increased by 21% 
from 2001 to 2009 [18]. Also, in Korea, the annual incidence rate of T1DM from 2007 
and 2013 was reported to increase from 2.73 to 5.02 per 100,000 [19]. However, in 
Japan, a lower incidence rate is reported between 1.5 – 2.5 per 100,000 among children 
(< 15 years old) [20]. The prevalence rate of T1DM in India is 31.9 per 100,000, where 
higher rates are seen in urban areas [21]. Moreover, in the Middle East Region, a high 
prevalence of T1DM is detected in young adults ( < 19 years old), in which 12.2% of 
T1DM cases are detected in Qatar, 33.5% in Saudi Arabia and 44.5 % in Kuwait. The 




improvement seen in regards to early diagnosis, disease monitoring, and treatment [14]. 
Another factor that could contribute to the increased rate of T1DM worldwide is the 
predominance of a sedentary lifestyle (mainly in westernized countries), which has 
been found to have a strong influence on autoimmune disease development, including 
T1DM [23]. A western lifestyle characterized by high fat/low fiber dietary intake and  
absence of physical activity, is considered to be a strong promoter of T1DM 
development by modulating the function of the immune system, mainly T-cells [24, 
25]. T1DM prevalence and incidence continue to increase worldwide and particularly 
in countries that have started to be exposed to a western-like lifestyle, such as Qatar 
and other countries in the Middle East.  
Diagnosis of diabetes is usually based on the concentrations of random blood 
glucose ( > 11.1 mmol/L), fasting blood glucose ( > 7.0 mmol/L), and abnormal oral 
glucose tolerance test. Measurement of HbA1c is considered a less sensitive tool for 
T1DM diagnosis and is usually used to monitor glycemic control [13]. Clinical features 
by themselves cannot differentiate between T1DM and other types of diabetes; 
therefore other factors, such as the age of diagnosis, genetic susceptible variants, and 
pancreatic autoantibodies should be considered [26]. Patients with T1DM, usually have 
autoantibodies against insulin, islet antigen 2, glutamate decarboxylase, and zinc 
transporter 8 [26]. A systematic review and meta-analysis study showed that the 
presence of islet autoantibodies increases the risk of developing T1DM both in the 
presence or absence of susceptible genetic variants [27].  
Regarding the health care management of T1DM patients, different types of 
treatments were developed,  to preserve insulin secretion [28]. One of the most 




regimen), which is known as multiple daily injection therapy. In this treatment, patients 
are given a basal insulin dose (long-acting) and prandial insulin dose (rapid-acting) in 
the form of multiple injections at various time intervals [28]. In addition, the doses are 
calculated according to the patient’s body weight, insulin sensitivity, and carbohydrate 
intake [29, 30]. A study showed that patients with T1DM treated with basal-bolus 
therapy have improved glycemic control and an HbA1c level of < 7 % [31]. Another 
common treatment used by T1DM patients is the insulin pump (known as subcutaneous 
insulin infusion, SCII), which provides a steady level of insulin through the use of an 
insulin pump device [28]. It has been shown that T1DM patients treated with insulin 
pump have a lower risk of having severe hypoglycemia or hyperglycemia episodes [32]. 
Also, the use of insulin pump therapy in children and adolescence with T1DM showed 
safety and effectiveness, where significant decrease in HbA1c level was detected and 
improved glycemic control was achieved [33].  
2.2 Pathogenesis of T1DM  
T1DM disease is a complex disorder as it involves the interaction of both genetic 
and environmental factors. T1DM pathophysiology involves also environmental 
factors, such as diet and microbiota. We hypothesize that the triple interaction between 
epigenetics, dietary factors, and gut microbiota can explain the disease development 
and the response to the treatment.  Several dietary factors are found to potentially 
influence T1DM by affecting gut microbiota and their metabolites [34, 35]. Also, 
different epigenetic modifications are found to have a significant role in T1DM 
development [7, 36]. 




Based on the genome-wide association studies (GWAS), different genes have been 
detected to be associated with increased risk for the development of T1DM, such as 
insulin gene (INS), non-receptor type 22 gene (PTPN22), and cytotoxic T-lymphocyte 
associated protein gene (CTLA-4) [37, 38]. However, the strongest association was 
detected with specific haplotypes of human leukocyte antigens DR/DQ (HLA-DR/DQ) 
[4].  
In addition, based on a twin study, identical twins have a higher risk of developing 
T1DM (69%) in comparison to siblings (47%) in the presence of autoantibodies [39] 
highlighting that genetics have an important role in T1DM pathogenesis. 
2.2.2 Environmental Factors 
Despite the inheritance of T1DM susceptible variants, genetic predisposition alone 
cannot explain the pathophysiology and sub-phenotypes of T1DM [5, 40-42].  
Environmental factors, such as infections, nutrition, mode of delivery, maternal 
age, and medication play a major role in the T1DM development [5]. This is supported 
by the phenomena of  high T1DM incidence in  genetically stable populations with a 
low genetic risk of developing T1DM [40-42]. Environmental factors trigger the 
development of T1DM either by its effect on intestinal function and the gut microbiota 
[43, 44] or on epigenetic mechanisms [45]. Since T1DM is a multifactorial metabolic 
disorder, its pathogenesis involves both genetic and environmental factors; however, 
recently the environmental determinants are getting more relevant in the development 
of T1DM. 
2.2.2.1 The role of nutrition in T1DM development and treatment 
 An important environmental trigger associated with T1DM development and 




fiber, fat and protein are known to be involved in the pathophysiology  and management 
of T1DM, the exact molecular mechanism is not clearly understood (Table 1). Since 
T1DM and its pre-clinical autoimmunity appear at an early age (3-9 months), the 
implication of early nutrition has been suggested to have a role in T1DM pathogenesis 
[49-52]. Breastfeeding was found to be an essential determinant of T1DM risk, where 
breastfed children showed a lower risk of developing the disease [49, 53]. This could 
be due to the presence of certain components in breast milk, such as lactoferrin, 
secretory immunoglobin A, lysosomes, and macrophages [50]. These components are 
known to have antimicrobial properties and are involved in the protection against 
different microbial antigens along with regulating the function of immune T-cells and 
B-cells [50]. On the other hand, cow's milk or formula milk intake at an early age (6-9 
months) increases the risk of T1DM development [50, 51], which could be as a result 
of specific fatty acids present in the cow's/formula milk (myristic, monounsaturated 
palmitoleic acid and  penta-decanoic) that induce pancreatic islet autoimmunity [54]. 
A similar finding was observed in an animal-based study, in which the A1 beta-casein 
present in cow’s milk altered glucose handling capacity by activating islet inflammation 
[55]. Furthermore, early introduction of cereals (age < 3 months) with or without gluten 
was found to promote T1DM development, while late introduction has no effect [52]. 
The effect of early cereal intake could be attributed to the immature immunity and 
undeveloped gut microbiota in children less than 6 months [52]. However, another 
study found that late introduction of gluten (age > 9 months) containing cereals is also 
associated with a high risk of autoimmunity and T1DM development [56]. Moreover, 
early probiotic supplementation within the first year of life is found to be associated 




linoleic acid (vegetable oil) is also found to be associated with reduced risk of β-cell 
autoimmunity in children (1-6 years old), while increased intake of myristic acid, 
monounsaturated palmitoleic acid, conjugated linoleic acid and pentadecanoic present 
in milk and ruminant meat is associated with a higher risk [46].   
 Diet in adult age can contribute as well to the pathogenesis and the progression 
of T1D. Vitamin D has an important role in the regulation of immune and metabolic 
related pathways, along with its  association with a lower risk of T1DM development 
[58, 59]. Vitamin D is known to down-regulate the response of T helper-1 lymphocytes 
[60], which could explain the possible association between vitamin D intake and the 
reduced risk of T1DM development. On the other hand, several other studies did not 
observe this effect of vitamin D supplementation [61, 62]. These discrepancies between 
studies could be attributed to a number of variables, which are type of supplement (i.e., 
calcitriol, alpha-calcidiol, or cholecalciferol), vitamin dosage, study participants age 
group, and diabetes duration. Furthermore, it is suggested that glycemic control and 
HbA1c could be modulated in T1DM patients based on their nutritional intake. An 
improvement in glycemic control was observed with the intake of a low 
carbohydrate/high-fat diet in T1DM patients [63]. However, increased risk of 
hypoglycemia and dyslipidemia development was associated with this type of diet  [63]. 
Furthermore, a  poor glycemic control characterized by elevated levels of HbA1c was 
found to be associated with the intake of low dietary fibers in T1DM patients [64]. 
Understanding the role and effect of different dietary components on T1DM 
development may aid in improving T1DM management and the development of a 
personalized therapeutic nutritional approach. One example is medical nutrition 




management of T1DM patients. The goal of MNT is to improve glycemic control, 
address individuals' needs, provide the needed calories, and create a plan for follow-up 
care for patients [28]. It is recommended that patients with T1DM use a carbohydrate 
diabetes meal planning system, which provides consistency in the carbohydrate 
content, thus reducing the fluctuation of blood glucose [65].  
 




Study subjects Age Major finding Ref. 
Breastfeeding Children with 
increased risk of 
T1DM based on 
HLA typing 
< 5 years old Breastfeeding during the introduction 
of new solid food, such as 
wheat/barley protected against 
development of T1DM in genetically 
susceptible children. 
[49] 




7 months – 16 
years old 
Breastfeeding reduces the risk of 
developing T1DM.  
Children who were not breastfed have 




Cow’s milk Children with 
increased genetic risk 
of developing islet 
autoimmunity or 
T1DM 
- High intake of cow's milk protein is 
associated with an increased risk of 
developing islet autoantibodies in 
patients with a low and moderate risk 
of developing T1DM. 
No association was found between 




 NOD mice fed with 
milk containing A1 
or A2 beta-casein 
component 
 
- Subclinical insulitis and signs of 
T1DM were seen in mice fed with A1 
beta-casein diet. 
A1 beta-casein diet altered glucose 







increased risk of 
T1DM 
9 months – 17 
years  
Early introduction of gluten-containing 
food (age < 3 months) increases the 
risk of developing autoimmunity and 
T1DM. However, the introduction of 
gluten after 6 months of age  does not 
affect the incidence of autoimmunity 





increased risk of 
T1DM based on 
HLA typing 
4- 10 years 
old 
Early supplementation of probiotics is 
associated with a reduced risk of 










2.2.2.2 Immune dysregulation and microbiota dysbiosis  
Under normal conditions, gut microbiota influences the immune system through 
activating adaptive immunity, compartmentalizing pathogens, and enhancing lymphoid 
tissue development [66]. As seen in many other pathological conditions, gut microbial 
dysbiosis associated with T1DM enhances gut permeability [67], resulting in the 
leakage of antigens and microbes into the systematic circulation and leading to b-cell 
damage and autoimmunity [68-70]. Different human and animal studies have been 
conducted to determine the microbial composition associated with T1DM. It has been 
found that T1DM patients have low gut microbiota diversity, low ratio of Firmicutes to 
Bacteroidetes, increased abundance of Bacteroides, and decreased Faecalibacterium 
prausnitzii and Lactobacillus [71]. A study done by Leiva and colleagues found that 
children with T1DM have an increased level of Bacteroides, Veillonella, Streptococcus, 
Ruminococcus, and Blautia compared to healthy controls. However, Bifidobacterium, 
Milk and 
ruminant meat fat 
Children positive for 
HLA-DQb1 
1 -6 years old increased levels of myristic acid, 
conjugated linoleic acid, 
monounsaturated palmitoleic acid, and 
pentadecanoic are positively associated 
with the risk of advanced b-cells 
autoimmunity. 
[46] 
Vegetable oil Children positive for 
HLA-DQb1 
1 -6 years old Increased level of linoleic acid reduces 
the risk of advanced β-cell 
autoimmunity. 
[46] 
Vitamin D T1DM patients  > 5 years old Sufficient levels of vitamin D 
preserves b-cells function and insulin 
secretion indicating that it provides a 






T1DM patients - Improvement in glycemic control 
observed by low levels of HbA1c and 
less glycemic variability 
Increased risk of hypoglycemia and 
dyslipidemia 
[63] 
Low fiber intake  T1DM patients  15-60 years 
old 
Elevated levels of HbA1c were 
observed in T1DM patients, thus 






Faecalibacterium, Roseburia, and Lachnospira were reduced [72]. The 
immunopathogenesis of T1DM due to microbial dysbiosis is not well understood, 
where both the innate and adaptive immune systems have been found to contribute to 
the development of T1DM [73, 74]. A study conducted using non-obese diabetic mice 
(NOD) found that TIR-domain containing adaptor inducing interferon-ß (TRIF) (a key 
adaptor molecule in the innate immune system) deficiency protected  against T1DM 
development possibly through altering the gut microbiota composition, as a significant 
reduction and increase in Proteobacteria and Firmicutes, respectively, was detected in 
TRIF deficient mice [74]. In MyD88-deficient NOD mice under normal conditions, no 
signs of diabetes were detected. However, under germ-free conditions, an advanced 
stage of diabetes was developed [73, 75]. This effect was also seen in other 
autoimmunity disorders, such as Celiac Disease, T2DM, obesity, and autoimmune 
uveitis [75]. In a study using the RIP-B7.1 C57BL/6 mouse model, diabetes was 
induced mainly due to microbial modulation through TLR3 and MyD88 pathways [76]. 
In general, there are two possible proposals on how microbiota could contribute to 
T1DM development: first, the enhanced intestinal permeability results in microbial 
leakage, thereby activating antigen-presenting cells and T-cells [67]. Secondly, the 
molecular homology of certain microbial products to Langerhans islets autoantigens 
could lead to the destruction of pancreatic b-cells and T1DM development [77]. 
Various research studies have proven the significant role of gut microbiota in the 
pathophysiology of T1DM  [78, 79].  
The relationship between dietary influence and gut microbiome composition in the 
development of T1DM in infants and children is not clearly understood and few studies 




colleagues to study the association between diet and microbiome in high-risk children 
found that Bacteroides abundance was found in children characterized by early 
introduction of non-milk diet and complex diet intake [80]. They also found that the 
level of  Bacteroides positively correlated with a high risk of early autoantibody 
development and low abundances of genes involved in butyrate production [80]. 
Another study found that early introduction of probiotics dietary supplement (0-27 
days) in high-risk children is associated with decreased risk of autoimmunity [81].  
2.3 The Role of Epigenetics in T1DM Development  
Epigenetics is the mechanism of activating and inhibiting the expression of genes 
by external factors, without affecting the DNA sequence [82]. Therefore, epigenetic 
changes are seen as non-genetic factors that interact with genes and are affected by 
genetic variations. In addition, epigenetic modifications are considered as 
consequences of the interaction between genetics and environment that results in 
making the DNA accessible for transcription factors and thus regulating gene 
expression [9, 83].  Several features could support the influence of epigenetics in T1DM 
development, which are high rates of discordance in monozygotic twins, increased risk 
of T1DM development in offspring of the affected father rather than the affected 
mother, and the increased T1DM incidence in a genetically stable population [7, 36]. It 
has been shown that epigenetic modifications, mainly DNA methylation, play an 
important role in the development of different autoimmune disorders, including T1DM 
[7, 36].  
2.3.1 The Role of DNA Methylation  
DNA methylation is the process of methyl group binding to the fifth carbon of 




methylcytosine [84]. Epigenetic mechanisms are found to be implicated in the early 
development and maturation of  β-cells [85]. In non-endocrine tissues, promoters of 
Glucagon and Insulin 2 [INS2] genes were found to be hypermethylated as compared 
to pancreatic β-cells [86]. Moreover, the different endocrine cell subtypes (α-cells, β-
cells, and δ-cells) were found to have different CpG methylation levels, indicating 
possible gene expression regulation in these cells [86]. DNA methylation is also found 
to be implicated in T1DM development as it alters the expression of genes responsible 
for insulin secretion, b-cell survival and autoimmunity [7]. The genome-wide DNA 
methylation profile generated from T1DM discordant monozygotic twins identified 132 
T1DM–associated methylation variable positions mostly in genes involved in 
apoptosis, inflammation, and the immune system [8]. Another study involving T1DM-
discordant monozygotic twins detected  88 CpG sites that are significantly methylated 
[87]. Therefore, genetics is not the only determinant of T1DM development, and DNA 
methylation plays an essential role in it, which is supported by twin studies (Table 2). 
Insulin (INS) gene and Interleukin 2 receptor a-chain gene (IL2RA) are important 
loci associated with the development of T1DM, and various methylation studies found 
that methylation of these genes are implicated in T1DM development. T1DM patients 
have an elevated level of methylation in CpG -180 and a decreased level of methylation 
in CpG -19, -135, and -234 in the INS gene, in comparison to healthy subjects [88]. 
Moreover, it has been found that the expression of the INS gene is regulated by the 
methylation of Ins1 exon 2 and Ins2 exon 1, which are induced by pro-inflammatory 
cytokines through activation of methyltransferases [89]. Regarding IL2RA, which 
encodes IL-2 receptors, T1DM patients are found to have elevated CpGs −456 and −373  




at CpGs −373 was found to be associated with sixteen SNPs known to be implicated in 
T1DM [90].   
There is evidence that shows the further implication of DNA methylation in T1DM 
associated complications, such as diabetic nephropathy [91]. One study showed that 19 
CpG sites were found differentially methylated in diabetic nephropathy and one of them 
located close to the transcription start site of UNC13B (rs13293564), which is 
implicated in  diabetes nephropathy development [91]. 
 
Table 2. Changes in DNA methylation associated with T1DM development in 
twins’ studies.  
Study 
subjects 







132 T1DM associated methylation variable 
positions were identified and found to be 
significant before and during clinical 
diagnosis.  
CD 14 + 
Monocytes  
Apoptosis, 
inflammation, and the 
immune system 
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concordant  for 
T1DM   
88 CpG sites have been found to be 
significantly methylated in monozygotic 
T1DM discordant twins.  
B-cells  Immune system 
(APOA4, C4BPA, 
CLEC7A) 
 cell signaling 
(APITDI, CALCA, 






DNA methylation did not differ between 
T1DM patients and their healthy co-twins, 
except for cg01674036 in CD 4 + T-cells.  
 
CD 4 + T-
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Immune system  








The prediabetic twin shows a differential 
methylation status between healthy and 
T1DM. 
CD 14 + 
Monocytes  





2.3.2 The role of other post-transcriptional and epigenetic regulatory events in 
T1DM development 
A micro-RNA (miRNA) ranges from 18-22 nucleotides and is a non-coding RNA 




different processes, such as proliferation, mitotic cell division, and programed cell 
death [95]. The miRNAs’ regulation of gene expression  is implicated in various 
autoimmune disorders [96, 97]. Regarding T1DM, it has been found that T1DM 
patients have up-regulation of miR-155-5p, miR-103a-3p, miR-210-3p and down-
regulation of miR-146a-5p [98]. The alterations in miRNAs could contribute to the 
pathophysiology of the disease through its influence on insulin secretion, the immune 
system, apoptosis, and the mitogen-activated protein kinase (MAPK) signaling 
pathway [98]. In children with T1DM, an up-regulation of a set of miRNA (miR-152, 
miR-30a-5p, miR-181a, miR-24, miR-148a, miR-210, miR-27a, miR-29a, miR-26a, 
miR-27b, miR-25, miR-200a) was observed and found to be involved in  ß-cell function 
and apoptosis [99]. The effect of miRNA in T1DM development through modulating 
the immune system is observed by the upregulation of miR-155-5p, which targets the 
mRNA of the transcriptional and immune response regulator gene (TCIM) [100]. The 
upregulation of miR-155-5p is also associated with inflammation through targeting the 
mRNA of toll-like receptors leading to the NF-kB pathway activation [101]. The 
downregulation of miR-146a-5p usually detected in patients with T1DM is found to be 
involved in the overproduction of IL-6 (a pro-inflammatory cytokine), thereby, 
suggesting the possible involvement of miR-146a-5p as a negative regulator of the NF-
kB pathway in T1DM [101, 102].  
Different modifications, such as acetylation, methylation and other mechanisms 
(ubiquitination and sumoylation), occur in the N-terminal region of histones [103]. 
Histone methylation defined as the attachment of methyl groups to arginine or lysine 
residues, it results in transcription regulation (activation /inhibition) based on the 




involves the function of histone-acetyltransferases (HATs) and histone-deacetylases 
(HDACs) enzymes responsible of the addition and removal of the acetyl group on 
lysine residues respectively [83]. Histone ubiquitination involves the function of 
ubiquitin ligases responsible for the addition of ubiquitin molecules to the conserved 
lysine residues [105]. For sumoylation, it involves the covalent binding of ubiquitin-
like modifier proteins to histones through ubiquitin analog enzymes [106]. 
Different studies have  shown the association between histone modification and 
T1DM development, in which H3 lysine 9 di-methylation (H3K9me2) was 
significantly increased in lymphocytes of T1DM patients [107]. There is also a strong 
association between increased H3K9me2 promoter activity with autoimmune genes, 
inflammatory pathway genes (TLR,p38-MAPK, and NF- κB), and T1DM susceptibility 
gene (CLTA4) [107]. Significant variations in H3K9 acetylation (H3K9Ac) levels at the 
upstream regions of HLA-DRB1 and HLA-DQB1 were also detected in T1DM patients 
[108]. Furthermore, THP-1 monocytes under the treatment of TNF-α and interferon-γ 
showed an enhanced expression of HLA-DQB1 and HLA-DRB1 with changes in 
H3K9Ac as seen in T1DM patients [108]. 
 
Table 3. a summary of research studies showing the association between other 
post-transcriptional and epigenetic modifications (miRNA and histone 



















The up-regulated miRNA detected  
is involved in the regulation of β-
cell functions and apoptosis.  
miR-25 has been found to be 
associated with glycemic control 
and β-cell function improvement.  
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as TIDM biomarkers since they 











miR-146a-5p in newly 
diagnosed T1DM 
patients (< 5 years) 
 
system, apoptosis, and insulin-





of T1DM > 10 
years  
 H3K9me2 Elevation of H3K9me2 in 
lymphocytes of T1DM patients 
a strong positive association 
between H3K9me2 promoter 
activity and genes involved in 




 Patients with 
the diagnosis 
of T1DM > 10 
years 
THP-1 cells  
H3K9Ac Variations in H3K9Ac levels at the 
upstream regions of HLA-DQB1 
and HLA-DRB1 was observed in 
T1DM patients  
Enhanced expression of  HLA-
DQB1 and HLA-DRB1 with 
changes in H3K9Ac after treatment 
with TNF-α and interferon-γ in 
THP-1 monocytes (in vitro) as 




2.4 The Interplay between Diet, Epigenetics and Gut Microbiome in T1DM  
 The link between diet and the epigenome and its contribution to T1DM development 
is not clearly understood. However, several studies suggested the possibility of specific 
nutrients to act as epigenetic effectors in T1DM development. Different studies showed 
the association between high fat intake and the risk of poor glycemic control, islet 
autoimmunity, and development of T1DM-related complications during both childhood 
and adulthood in T1DM patients [109, 110]. It was also found to act as an epigenetic 
modulator, where it impacts a transcription factor essential for β-cell survival known 
as TCF7L2 [111].  Aberrant TCF7L2 promoter methylation in β-cells was observed in 
mice treated with a high-fat diet (HFD - 45kcal% fat) in comparison to mice given a 
normal diet [111]. Even though  the implication of  TCF7L2 was commonly detected 
in T2DM patients, it was also observed in a subset of non-obese T1DM patients [112]. 




cells of male mice offspring leading to proliferation defects and insulin degranulation 
[113]. However, early transition from a high-fat diet to a normal diet protected pups 
from developing insulin resistance [113]. It has been found that maternal high fat diet 
causes insulin receptor substrate-2 gene (IRS-2) hypermethylation and mitogen-
activated protein kinase kinase-4 gene (MAP2K4) hypomethylation in mice offspring. 
This results in a decreased expression of IRS-2 and increased expression of MAP2K4, 
thus elevating the pup’s risk of developing diabetes [114].  
 The interplay between diet and epigenetics was also found to be related to insulin 
signaling pathways and glucose metabolism. Through the use of the grass carp, 
Ctenopharyngodon idellus, whole-genome DNA methylation analysis revealed no 
significant difference in methylation levels under different dietary conditions (high 
carbohydrate diet/ normal diet) [115]. In the case of high carbohydrate intake, the 
differentially methylated genes in Ctenopharyngodon idellus were enriched in 
pathways related to insulin signaling, glucose and lipid metabolism. Moreover, the 
differentially methylated genes involved in obesity and T2DM detected in 
Ctenopharyngodon idellus, were similar to those found in mammals [115].  
 Although, the effects of diet on the microbial composition of the gut have been 
demonstrated in many animal models of T1DM, little is known regarding such effects 
in humans, due to the lack of long-term and placebo-controlled trials [68-70]. Specific 
dietary factors identified as potentially influencing T1DM, such as breastfeeding, and 
low-fat/high-fiber diet, are known to influence the gut microbiota composition and its 
products [34, 35]. As dietary fibers are digested only by gut microbiota present 
primarily in the lower gastrointestinal tract, fermentation of these fibers produces short-




proposal that SCFAs play an important protective role against T1DM is supported by 
the greater capacity for synthesis of SCFAs in healthy subjects compared to T1DM 
patients [79]. These SCFAs are found to activate specific free fatty acid receptors 2/3 
(FFAR2 and FFAR3) leading to the inhibition of the histone deacetylase, and thus 
resulting in the activation of T-regulatory cells and inhibition of the inflammatory 
cascade [119].  
 The link between the three factors, which are diet, epigenetics, and microbiome, and 
their mechanistic contribution to T1DM development is yet to be identified (Figure 2). 
However, as observed in T2DM, it can be proposed that SCFAs (butyrate, acetate, and 
propionate) cause-specific activation of FFAR2 and FFAR3, which inhibit histone 
deacetylase. This results in the inhibition of NF-kB [120] and the activation of ERK 
and MAPK pathways [121] in intestinal regulatory T-cells, therefore down-regulating 
the inflammatory cascade [122]. Moreover, binding of SCFA to the promoter region of 
FFAR3 was found to reduce methylation of the CpG islands in T2DM patients [123]. 
Since T1DM and T2DM share similar genetic and environmental factors, further 










Figure 2. Schematic representation of the interplay between diet-epigenetic-




Chapter 3: Materials and Methods 
 
3.1 Study subjects’ recruitment and sample collection 
This study was conducted at Sidra Medicine. The study has been approved by the 
institutional review board at Sidra Medicine (IRB number: #1708012734) and Qatar 
University (IRB number: QU-IRB1411-E/20).  
T1DM patients were approached and introduced to the study after their medical 
appointment in Sidra’s endocrinology clinic. T1DM patients were selected according 
to the following criteria: age ranges from  6 – 12 years, had no chronic condition other 
than T1DM, no history of cancer or any familiar genetic disease, no history of antibiotic 
treatment in the last three months and the onset of T1DM diagnosis is more than one 
year. For the T1DM-obese subjects, the same criteria were followed along with a BMI 
percentile value higher than 95th percentile. In regards to the obese group, the same 
inclusion criteria were applied, along with a BMI value higher than 95th percentile and 
no history of diabetes diagnosis or glucose intolerance. Healthy lean controls were 
recruited from children of Sidra’s staff who volunteered to participate in the study. 
Healthy lean controls should have no history of any chronic condition including 
diabetes diagnosis or glucose intolerance. Consent/assents forms were provided by the 
subjects and their parents who agreed to participate in this study.  
The recruited subjects were divided into four groups: 35 T1DM patients, 16 obese 
subjects, 9 T1DM-obese patients, and 12 as lean healthy subjects. The subject’s clinical 
information, such as family history of diabetes, medication, diabetes duration, and 
insulin treatment were provided by the physician during the visit.  Also, 24-hrs dietary 
recall  was collected during the interview to determine the dietary intake of the study 




and waist circumference.  Several biomedical tests were performed, including a lipid 
profile, liver function tests, thyroid tests (TSH, T4), and HbA1c.  
From each study subject, blood samples were collected by the phlebotomist (3 ml 
of blood in a 6 ml Tempus Thermo Fisher Scientific tube containing RNA preservative 
solution) for DNA and RNA extraction. Samples were transported to the lab within 24 
hours upon collection, in which aliquots of each sample were transferred into 1.5 micro-
centrifuge tubes and stored at -80ºC immediately. A total of 72 participants were 



























Study subjects were recruited at Sidra’s endocrinology 
clinics 




The following was collected  
•   Biochemical tests and physical measurements  
•   24-hours dietary recall 
•   HbA1c level, diabetes duration and type of treatment  
•   Blood samples for DNA extraction  
  




T1DM Patients:  
T1DM = 35  
T1DM-Obese = 9 
 
Controls: 
Healthy = 12 





Figure 3. Schematic flow chart of the research plan. 
 
 
3.2 Clinical data analysis  
The clinical data obtained from study subjects include anthropometric 
measurements (height, weight, waist circumference), liver function tests, lipid profile, 
thyroid and pituitary gland hormones, micro-albumin/creatinine ratio, and blood 
pressure. Tests related to diabetes include glucose level, HbA1c, insulin/carbohydrates 
ratio, insulin dose (Kg/unit), and treatment type.  
3.3 Dietary analysis   
The dietary data obtained from the subjects' 24-hrs recalls were uploaded on 
Nutritionist Pro software (Axxya Inc). Dietary meals that were not found in Nutritionist 
Pro software, such as Arabian meals, were added as a new recipe by adding the 
ingredients and the serving amounts in the software. After uploading the dietary data, 
the average daily intake of macronutrients and micronutrients was calculated per 
subject and per group.  
3.4 DNA extraction from a blood sample  
DNA extraction was conducted using QIAamp® DNA kit (catalog no #51106, 
Qiagen, Germany) according to the manufacturer’s instructions. However, a different 
concentration was used for proteinase K (20mg/ml) and the sample (40µl and 400µl 
respectively) in order to obtain a higher DNA concentration. Measurements of the other 
reagents were adjusted accordingly, except for the washing buffer reagent. In the 
elution step, 100 to 200 µl of the buffer AE was added in the QIAamp Spin Column 




Scientific, USA) was used to measure DNA quantity and quality. The eluted DNA was 
then transferred into a new Eppendorf tube and stored at -80ºC for further analysis.  
3.5 DNA methylation analysis 
The extracted DNA samples (200-500 ng) were distributed in a 96-well plate and 
processed using the Zymo EZ DNA Methylation Kit for bisulfite conversion as per the 
manufacturer’s instructions. This kit converts unmethylated cytosines (C) in genomic 
DNA to uracil (U), though leaving methylated cytosines unchanged for methylation 
analysis. First, the bisulfite converted DNA was denatured and neutralized before 
amplification. The samples were denatured for 10 minutes at room temperature using 
0.1 N NaOH. The denatured DNA was then  amplified in an overnight step at 37°C for 
20-24 hours. Afterwards, a controlled enzymatic fragmentation was performed, which 
uses an endpoint fragmentation process  to prevent over fragmentation. DNA 
fragmentation was accomplished by centrifuging the plate at 280 xg, and addition of 
50µl FMS followed by incubating the plate into a preheated heat block for 1 hour at 
37°C. The fragmented DNA then underwent isopropanol precipitation with 
centrifugation at 4°C before being resuspended in a hybridization buffer. The 
resuspended DNA was loaded onto one of 8 positions on a barcoded BeadChip slide 
and incubated overnight in the hybridization oven at 48°C. A washing step was 
performed to remove unhybridized DNA from the BeadChip slide using PB1 at room 
temperature. Finally, BeadChips was coated with XStain BeadChip Solution 4 (XC4)  
and dried prior to scanning using the iScan system.  
Then, genome-wide DNA methylation profiling from the study subjects was 
performed in the Genomic Core at Sidra Medicine using the Illumina Infinium EPIC 




of over 850,000 methylation sites across the genome at single-nucleotide resolution, 
imaged with the Illumina iScan platform. A number of quality control steps were 
performed on the raw methylation data. First, probes with a mean detection level P-
value <0.05 were used for subsequent analysis. Second, the data were normalized and 
the background was corrected using the methylation module (1.9.0) available on 
GenomeStudio (v2011.1) software. The DNA methylation level at each CpG site was 
given for each sample by the following formula: β = 	   $
$%&
	  . 100%, where M represents 
signal strength of methylated CpG and U is the signal strength of unmethylated CpG.  
The generated β-value was exported to Partek Genomics Suite version 7.0 in the 
form of .idat files for differential methylation analysis and data quality/quality control 
analysis (Appendix B, figure S2). The data was normalized within and between the 
groups using Illumina normalization. Probes located on X and Y Chromosomes were 
excluded from the analysis.  A two-way ANOVA test was conducted to detect 
differential methylation analysis, in which M-values were generated from the β-values 
using the following formula M = 	  Log2	  ( 1
231
	  ). The gene marker list, with the 
significant methylated genes, was generated using ANOVA with a P-value <0.05 and 
FDR >2 and by measuring the fold change. 
3.6 Functional classification and gene network analysis 
 To cluster differentially regulated genes based on their common 
functionality, a set of genes was analyzed for gene ontology and pathway analysis 
using  Ingenuity Pathway Analysis (IPA). The differentially methylated genes that 
are FDR adjusted were added to the software to investigate canonical pathways, 




3.7 Gut microbiome and Short Chain Fatty Acid (SCFA) analysis  
 The metagenomic analysis data (16S rDNA sequencing) of the gut microbiome 
for the study subjects were already available from previous data analysis. Alpha 
diversity and beta diversity analyses were performed using the R package. To identify 
microbial biomarkers among the different groups, Linear discriminant analysis effect 
size (LEfSe) analysis was performed with the cut-off value of LDA >2.0.   
SCFA analysis was performed in Deep Phenotyping Core. Internal standard 
solutions containing deuterated fatty acids were mixed with the aliquots of the study 
subjects' stool samples to undergo derivatization with ethyl chloroformate producing 
ethyl esters. Analysis of ethyl esters was performed by Agilent 7890B Gas 
Chromatograph with 5977 Single Quadrupole Mass Spectrometer. Data analysis was 
conducted using a MassHunter WorkStation and SCFAs concentration was expressed 
in µmol/g of stool. 
3.8 Integration analysis   
The back-end of the network analysis was primarily based on Python and C++. 
Through the use of PHP, server connections were  established, and front-end design 
was based on HTML, CSS, and Javascript. In this analysis, both prevalence and 
occurrence-based filtration criteria were used. Prevalence indicates the minimum 
abundance at which a given feature must be present in a sample. Whereas occurrence 
indicates the minimum number of samples in which the given feature must prevail at 
the prevalence threshold.  To normalize and filter the data, total sum scaling method 
was performed. Microbial OTU abundance with the metadata was correlated using 
NAMAP correlation matric [125]. Finally, data were visualized based on Cytoscape.js, 




3.9 Statistical analysis  
Generated results were evaluated using logistic regression with covariates such 
as age, and sex to derive adjusted odds ratios and 95% confidence intervals. For the 
differential CpG data analysis, a statistical one way ANOVA was performed to 
compare the average of DNA methylation level between the four groups: T1DM, 
T1DM-OB, obese and healthy controls. Clinical and dietary data were further analyzed 
by ANOVA- Turkey multi-comparison analysis for normally distributed data and 
Kruskal-Wallis test for not-normally distributed data.  A two-sided P-value of < 0.05 
was considered statistically significant. Categorical data were reported as the number 
or proportion of subjects within a category, while continuous data were reported as 







Chapter 4: Results and Discussion  
4.1 Results 
4.1.1 General characteristics of the study subjects  
We recruited a total of 72 subjects divided into four groups: 35 T1DM patients, 
9 T1DM-obese patients, 16 obese subjects, and 12 as lean healthy subjects. In the 
T1DM group, the mean age was 11.5 years old with a mean BMI value of 18.8±3.7 
kg/m2 in the average of normal weight and half of the study subjects being males (50%). 
Qatari nationals accounted for 54.3% of the study subjects and expatriates living in 
Qatar accounted for 45.7%. The HbA1c average and diabetes duration of the T1DM 
study subjects were 7.811% , 9 years, respectively. Out of the 36 participants, only 9 
subjects are given the Continuous Subcutaneous Insulin Infusion (CSII) treatment. On 
the other hand, nine participants were in the T1DM-obese group, with a mean age of 
10.5 years and a mean BMI value of 28.95±2.0 kg/m2. The HbA1c average and diabetes 
duration of the T1DM-obese study subjects were 8.42% and5 years, respectively.  Also, 
only 5 subjects (55.5%) are using CSII. For the obese group (n= 16), the mean age was 
11 years with a mean of 33.9±7.4 kg/m2 for the BMI. Most of the study subjects in this 
group were males (62.5%) and Qatari nationals (75%). Regarding the healthy group, 
the mean age was 11 years with an HbA1c mean value of 4.86%. In this group, males 
account for 41.6% and most of the participants were expatriates living in Qatar (83.3%). 












Table 4. General characteristics of the study subjects.  
 
Note: Values are reported as mean±std dev and in percentage, wherever applicable. CSII: Continuous 




4.1.2 Clinical Characteristics analysis of the study subjects  
Different physical and chemical measurements were obtained from the study 
subjects, which are blood pressure measurements, triglycerides, HDL, LDL, liver 
function tests, vitamin D, and thyroid-related hormones (Table 5). Significance was 
observed in the measurements of systolic and diastolic blood pressure (SBP/DBP) (One 
Way ANOVA SBP p-value = 0.0048 / DBP p-value = 0.0060 ). T1DM-OB and obese 
subjects had a significantly higher SBP (p-value= 0.0386) and DBP (p-value= 0.0032)  
respectively in comparison to the T1DM group based on multi-comparison Tukey's test 
Parameters T1DM (n=35) TIDM-OB (n=9) Obese (n=16) Healthy (n=12) 
Age in years (mean±std 
dev) 
11.5±2.12 10.5±3.53 11±4.24 11±1.4 
Male gender; n (%) 18 (50%) 3 (33.3%) 10 (62.5%) 5 (41.6%) 
Nationality; n (%) Qatari n= 19 (54.3%) 
Expats n= 16 (45.7%) 
Qatari n=  6 (66.6%) 
Expats n=   3 (33.4%) 
Qatari n=  12 (75%) 
Expats n=   4 (25%) 
Qatari n=  2 (16.6%) 
Expats n=  10 (83.3%) 
BMI  kg/m2 (mean±std 
dev) 
18.8±3.7 28.95±2.0 33.9±7.4 17.1±2.7 
HbA1c (mean±std dev) 7.811±1.27 8.42±2.44 5.49±0.27 4.86±0.37 
CSII n (%) 9 (25.7%) 5 (55.5%) NA NA 
Diabetes Duration (years; 
mean±std dev) 
9±4.24 5±2.82 NA NA 
Dietary data; n (%) 33 (94.2%) 9 (100%) 16 (100%) 12 (100%) 
Clinical data; n (%) 35 (100%) 9 (100%) 14 (87.5%) 9 (75%) 
DNA methylation ; n (%) 30 (85.7%) 9 (100%) 16 (100%) 12 (100%) 
Gut microbiome data; n 
(%) 
24 (68.5%) 4 (44.4%) 10 (62.5%) 11 (91.6%) 




(Figure 4). For the biochemical analysis, significance was observed in the 
measurements of LDL, AST, ALT, and TSH (Table 5). T1DM-OB showed a 
significantly higher level of LDL in comparison to T1DM and obese subjects with a 
multi-comparison Tukey's p-value of 0.0227 and 0.0116, respectively (Figure 5A). 
Measurements of TSH level was also observed to be significantly different between the 
four groups (One way ANOVA p-value = 0.023), but non-parametric Kruskal-Wallis 
test showed non-significance (Figure 5B). For the liver function tests, significance was 
only observed in the measurements of AST and ALT (One way ANOVA p-value = 
0.012 and 0.0092, respectively). T1DM subjects have significantly lower AST levels 
in comparison to obese (Kruskal-Wallis test p-value = 0.0287) and higher ALT levels 
compared to healthy subjects (Tukey's p-value = 0.017), respectively (Figure 5C and 
D).  
 
Table 5. Physical and clinical characteristics of study subjects  
Parameter 
(mean±std dev) 




104.0±7.31 112.5±5.31 111.3±9.0 103.3±10.02 0.0048 
Diastolic blood 
pressure(mmHg) 
66.39±5.18 69.75±4.92 72.25±5.66 68.67±5.41 0.0060 
Triglycerides 
(mmol/l) 
1.04±0.49 1.68±1.3 1.09±0.47 1.31±0.97 ns 
HDL (mmol/l) 1.71±0.43 1.35±0.21 1.52±0.62 1.40±0.23 ns 
LDL (mmol/l) 2.31±0.68 3.11±0.81 2.12±0.84 2.33±0.60 0.0152 
AST (IU/L) 17.91±5.70 22.4±5.83 26.79±10.97 17.22±4.79 0.012 
ALT (IU/L) 21.49±5.40 22.2±8.09 26.79±10.97 29.67±4.38 0.0092 
TSH (mIU/L) 2.28±1.13 4.58±4.64 3.47±1.87 1.77±1.01 0.023 




Vitamin D (nmol/L) 51.06±16.81 37.56±8.56 45.11±19.81 39.89±12.63 ns 
Note: Values are reported as mean±std dev. P-value was calculated using One Way ANOVA. HDL: 
High-Density Lipoprotein; LDL: Low-Density Lipoprotein; AST: Aspartate Transaminase; ALT: 

















Figure 4. Significant systolic and diastolic blood pressure measurements SBP/DBP  
between the different study groups.: T1DM, T1DM-OB, obese and healthy 
controls. T1DM subjects have significantly lower systolic and diastolic blood pressure. 
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Figure 5. Significant clinical data analysis between the different study groups: 
T1DM, T1DM-OB, obese and healthy controls. A: LDL levels significantly 
increased in T1DM-OB compared to T1DM and obese groups. B: difference in the TSH 
level between the different four groups. C: decreased levels of AST in T1DM subjects 
compared to obese subjects. D: decreased levels of ALT in T1DM subjects compared 
to healthy controls. P-value was calculated using Tukey's p-value and the Kruskal-
Wallis test was used for non-parametric data (AST and TSH). LDL: Low-Density 
Lipoprotein; AST: Aspartate Transaminase; ALT: Alanine Transaminase; TSH: 
Thyroid Stimulating Hormone.  
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4.1.3 Macronutrient and micronutrient dietary analysis of the study subjects  
 A 24-hour dietary recall was obtained from each subject and then uploaded on 
Nutritionist Pro software (Axxya Inc) to determine the significant dietary factors and 
dietary patterns present in the four groups. Macro- and micro-nutrients were measured, 
including Kcal, carbohydrates, proteins, fats (SFA, MUFA), sugars (glucose, lactose, 
etc.), vitamins (vitamin A, C, D, etc.), and minerals (iron, calcium, etc.). The ANOVA 
analysis showed a significant difference in the intake of saturated fatty acids (SFA), 
vitamin-K, and pantothenic acid with a p-value of 0.018, 0.0312, and 0.0273, 
respectively (Table 6). Multigroup comparison test confirmed that T1DM subjects were 
found to have a significant decrease in the intake of SFA compared to healthy controls 
(Tukey's p-value= 0.0170) (Figure 6). Whereas vitamin K was significantly lower in 
the T1DM group compared to the obese (Kruskal-Wallis's p-value = 0.0214) (Figure 
6). The intake of SFA in the T1DM group is 9.7% (14.89 g), which is considered close 
to the recommended intake of SFA (10% of the total Kcal intake) [126]. However, 
T1DM subjects have a mean value of 12.3 g fiber of the total dietary intake, which is 
lower than the recommended value (25 g per day) [126]. 
 
Table 6. The difference in nutrients intake between study groups. 
 T1DM T1DM-OB Obese Healthy p-value 
Kcal  1369±431.4 1331±556.6 1506±686.2 1509±515.7 ns 
Protein (g) 60.6±25.23 70.24±39.0 59.1±16.46 49.7±16.9 ns 
Carbohydrate (g)  171.2±71.6 147.4±68.3 167.9±102.2 176.8±62.6 ns 
Total Fats (g) 47.24±19.5 52.17±23.6 62.17±27.5 63.3±28.65 ns 
Cholesterol (g) 229.8±161.8 263.1±195.4 194.8±84.2 130.9±105.3 ns 
MUFA (g) 16.8±8.27 18.55±10.83 22.1±11.69 17.9±9.7 ns 
PUFA (g) 10.59±6.22 10.1±5.53 10.68±7.3 11.01±7.1 ns 
TSFA (g) 0.30±0.33 0.46±0.53 0.76±0.85 0.17±0.2 ns 
SFA (g) 14.89±6.298 17.90±9.734 21.01±9.427 24.43±15.67 0.018 




Total Sugars (g) 53.5±37.2 54.9±45.6 55.6±42.5 71.7±32.5 ns 
Calcium (mg) 558±345.2 719.6±496 716.7±385.2 461.2±226.6 ns 
Iron (mg) 11.75±8.7 12.9±10.9 16.48±13.9 10.79±5.14 ns 
Vitamin A (IU) 3047±4363 5057±7212 2447±1436 2008±3392 ns 
Vitamin A (RAE) 400.3±357.9 468.7±423.3 318.2±209.8 312.9±256.9 ns 
Beta-Carotene 
(mcg)  
1076±2052 2342±3791 993.1±736.8 1626±2625 ns 
Vitamin C (mg) 41.2±32.9 57.2±51.4 69.3±60.8 90.8±107.9 ns 
Vitamin D (mcg) 3.76±3.25 3.67±3.4 3.5±3.9 2.87±2.4 ns 
Vitamin-K (mcg) 56.37±121.5 91.65±159.6 138.5±177.2 57.20±42.46 0.0312 
Vitamin E (mg) 0.81±1.5 0.25±0.28 0.55±0.90 0.74±1.4 ns 
Vitamin E (Alpha – 
Tocopherol) (mg) 
4.37±2.3 3.95±2.2 6.3±4.3 4.56±2.9 ns 
Thiamin (mg) 1.14±0.7 1.05±0.74 1.09±0.47 1.03±0.39 ns 
Folate (mcg) 98.08±50.9 121.6±47.8 125.1±57.5 141.6±88.7 ns 
Pantothenic acid 
(mg) 
3.649±1.931 3.669±1.899 2.498±1.319 2.166±0.7914 0.0273 
Note: Values are reported as mean±std dev. P-value was calculated using One Way ANOVA. SFA: 

























A ANOVA P-value=  0.018 
Saturated Fatty Acid (SFA) 
B 
Vitamin K 
ANOVA P-value=  0.0312 
C 
Pantothenic Acid  




Figure 6. Significant nutrients intake between the different study groups: T1DM, 
T1DM-OB, obese and healthy controls. A: SFA intake was significantly lower in 
T1DM subjects compared to healthy. B: vitamin K intake was significantly lower in 
T1DM subjects compared to obese. C: the difference in the pantothenic acid between 
the different four groups: T1DM T1DM-OB, obese and healthy. P-value was calculated 
using Tukey's p-value for SFA and Kruskal-Wallis test for non-parametric data 
(vitamin K and pantothenic acid). SFA: Saturated Fatty Acid.  
 
 
4.1.4 Differentially methylated genes detected between the different groups  
In order to detect the DNA methylation level at each CpG site from each study 
subject, raw methylation data generated from the Illumina Infinium array were 
imported to the Genome Studio software, in which global methylation level was 
measured from the Beta values. We did not observe any significant variation in the 
DNA methylation level detected in the four groups. Most of the patients have a 
methylation level of over 800,000 probes (Appendix B, figure S2). In addition, the 
comparison between the four groups (T1DM, T1DM-OB, healthy and obese) showed 





















Figure 7. CpG DNA methylation levels between study groups: T1DM, T1DM-
OB, Healthy, and Obese with probes with a mean detection level P-value <0.01. 
One way ANOVA was used to compare between groups. ns: non-significant.  
 
 
Our next analysis was to determine the differentially methylated genes between 
the different groups focusing on three main comparisons, which are T1DM vs Healthy, 
T1DM-OB vs T1DM, and T1DM-OB vs Obese. A total of 1153, 955, and 946 genes 
with a p-value<0.05 were differentially methylated between T1DM vs Healthy, T1DM-
OB vs T1DM, and T1DM-OB vs Obese respectively (Appendix B, Table S1). 
However, using a  more statistically stringent conditions of a  P-value <0.05 and  a FDR 
>2 only two differentially methylated genes were detected (Table 7). In our analysis, 
we have identified the differential methylation of the suppressor APC domain 
containing 1 (SAPCD1) in T1DM patients compared to healthy controls a fold change 
of 4.9 (P-value= 0.00349). Moreover,  we have also observed the differential 
methylation of DnaJ heat shock protein family (HSP40) member C7 (DNAJC7) in 
T1DM-OB subjects compared to obese with a fold change of -9.1 (P-value = 
0.0000000262). In addition, the mean difference (mean±SD) was calculated from Beta 
values of each gene. For the SAPCD1 gene a mean difference of 2.29±71.9 was 
observed between T1DM and healthy control. Whereas, the DNAJC7 showed a mean 
difference of 0.22±111.9 between T1DM-OB and obese subjects. No FDR-adjusted 
genes were identified between T1DM-OB and T1DM.    
 
Table 7. Differentially methylated genes detected between T1DM vs Healthy and 
T1DM-OB vs Obese. 
Gene 
Symbol 









SAPCD1 suppressor APC 
domain containing 1  
4.9  T1DM compared to 
healthy controls 
0.00349 
DNAJC7 DnaJ heat shock 
protein family 
(HSP40) member C7  




Our functional pathway analysis of the FDR-adjusted gene between T1DM and 
healthy controls conducted by IPA showed no significant canonical pathways. 
However, three disease pathways were found significant between the two groups, 
which are cardiovascular diseases, organismal injury and abnormalities, and 
reproductive system diseases (Figure 8). In the case of T1DM-OB, we have identified 
some significant canonical pathways in comparison to the obese group, which are 
aldosterone signaling in epithelial cells, xenobiotic metabolism CAR/PXR pathways, 
NRF2 mediated oxidative stress response, and protein ubiquitination pathway (Figure 
9). Moreover, a number of significant diseases were identified between the T1DM-OB 
and the obese group, which are gastrointestinal disease, hepatic system, metabolic 
disease, organismal injury and abnormalities, cancer, and reproductive system diseases 
(Figure 10A). Molecular and cellular function analysis showed  several functions to be 
significantly different between the two groups, which are post-translational 
modifications, protein folding, lipid metabolism, molecular transport, and small 










Figure 8. Significant disease pathways detected between T1DM and healthy 






















Figure 9. Significant canonical pathways detected between T1DM-OB and obese 




























p=0.0004 p=0.0003 p=0.1567 p=0.1955 p=0.002 p=0.002 p=0.045 p=0.020
Figure 10. Significant disease pathways (A) and molecular and cellular functions 
(B) detected between T1DM-OB and obese subjects generated by IPA. 
 
4.1.5 Gut microbial composition and SCFA analysis of the study subjects  
The gut microbial composition and abundance were previously analyzed in our 
study groups. Gut microbial relative abundance in the phylum and genus level is 
presented in Appendix C, figure S3. Gut microbial diversity analysis, measured by the 
alpha-diversity, showed significance in the genus richness (Observed and Chao1 
indexes) among the four different groups (Observed p-value = 0.0004; Chao1 p-value 
= 0.0003) (Figure 11). We have also observed a significant lower microbial abundance 
and genus richness in T1DM subjects in comparison to healthy controls (Observed p-
value = 0.002; Chao1 p-value = 0.002; Shannon p-value = 0.045; Simpson p-value= 
0.020) (Figure 10). No difference was observed in the beta-diversity analysis among 





















[ANOSIM]  r:  0.047716;;  P<0.134
Figure 11. Alpha-diversity (gut microbiome) analysis of the study subjects. A: 
significance in the genus richness (Observed and Chao1 indexes) among the four 
different groups. B: T1DM subjects showed lower microbial abundance and genus 

















Figure 12. Beta-diversity (gut microbiome) analysis of the study subjects. No 
difference was observed in the beta diversity among the four groups. Beta-diversity was 
visualized using Principle co-ordinations generated with the Bray–Curtis distance 
metric by QIIME. Analysis of group similarity (ANOSIM) was measured between 




Furthermore, in this study, LEfSe analysis was used for the identification of the 
significant gut microbial markers between the different study groups with the cutoff 
value of LDA >2.0. Rikenellaceae, Christensenellaceae, Weissella, Lactobacillales, 
Anaerofustis, Leuconostocaceae, and Brachyspira were found to be significantly 
enriched in the healthy controls compared to the T1DM patients (Figure 13). No 
specific gut microbial marker was identified for the T1DM group. In regard to the 
T1DM-OB group, Roseburia, Bifidobacterium, Neisseria, Blautia, Lachnospiraceae, 
among others, were found to be significantly enriched in comparison to obese subjects 




Bifidobacterium, Blautia, Lachnospiraceae, among others, were found to be 















Figure 13. Significant gut microbial markers between T1DM and healthy controls. 
Significant enrichment of Rikenellaceae, Christensenellaceae, Weissella, 
Lactobacillales, Anaerofustis, Leuconostocaceae, and Brachyspira in the healthy 

































Figure 14. Significant gut microbial markers between T1DM-OB  with obese and 
T1DM subjects. A: significant enrichment of Roseburia, Bifidobacterium, Neisseria, 
Blautia, Lachnospiraceae, etc. in T1DM-OB compared to obese subjects. B: significant 
enrichment of Roseburia, Bifidobacterium, Blautia, Lachnospiraceae, etc. in T1DM-




The metabolic analysis was also conducted to measure the concentration of 
SCFAs in the study subjects and determine the significant microbial metabolites among 
the four groups. The SCFAs measured in this study were ethanoic acid, propionic acid, 
isobutanoic acid, butanoic acid, 2-methylbutanoic acid, isopentanoic acid, pentanoic 
acid, 3-methylpentanoic acid, 4-methylpentanoic acid, and hexanoic acid. Based on 
ANOVA analysis only butanoic acid showed significance that was significantly 
increased in T1DM-OB compared to the healthy control (One Way ANOVA p-value = 















Figure 15. The difference in the butanoic acid between the different four groups: 
T1DM T1DM-OB, obese and healthy controls. Butanoic acid was significantly 
increased in the T1DM-OB group compared to healthy controls. P-value was calculated 
using the Kruskal-Wallis test.  
 
 
4.1.6 Correlation between DNA methylation with dietary factors, gut 
microbiome, and SCFAs using network analysis  
 
To identify the potential link of DNA methylation with diet and gut microbial 
composition in the development of T1DM disease, we have conducted network analysis 
between CpG methylation levels from the study subjects of the four groups with dietary 
factors and the gut microbiome. No network association was found between diet and 
DNA methylation in T1DM, T1DM-OB, and obese groups. However, in the healthy 
controls, a positive correlation was detected between CpG methylation level and folate 
and thiamin intake (Figure 16).  
Regarding the association between DNA methylation level and gut microbiome, 
no network association was found in the T1DM-OB group. In contrast, T1DM patients 
showed a negative correlation between detected CpG methylation level and 
Faecalibacterium (Figure 17 A). In the healthy controls, a negative correlation was 
detected between methylation level with Butyricimonas, Lachnospira, and Clostridium 
ANOVA P-value=  0.025 







(Figure 17 B). However, Lachnospira was found to be positively correlated with 
methylation level in the obese group. Network analysis also showed a negative 
correlation between methylation and Odoribacter in Obese subjects (Figure 17 C). 
Furthermore, network analysis showed no association between CpG methylation levels 
and SCFAs.  
We have also conducted network analysis of CpG methylation levels with HbA1c 
and diabetes duration, however no significant correlation was observed. CpG 
methylation level was found to be positively correlated with HbA1c and negatively 
correlated with diabetes duration in T1DM-OB subjects (P-value = < 0.1) (Appendix 









Figure 16. Network analysis between CpG methylation level and dietary factors 
in healthy controls. Note: blue line indicates a positive correlation, the red line 




























Figure 17. Network analysis between CpG methylation level and the gut 
microbiome. A: correlation observed between methylation level and microbial genus 
in T1DM subjects. B: correlation observed between methylation level and microbial 
genus in healthy controls. C: correlation observed between methylation level and 
microbial genus in obese subjects. Note: blue line indicates a positive correlation, the 
red line indicates a negative correlation.  
 
4.1.7 Correlation between dietary factors and gut microbiome using network 
analysis  
 
Network analysis was conducted to identify the potential correlation of gut 
microbiome with different nutritional factors in all the study groups. In the T1DM 
group, a positive correlation was found with few dietary factors, which are folic acid, 
biotin, vitamin E, iodine, lactose, vitamin D, phosphorus, and trans-fatty acids (Figure 
18A). Folic acid was found to be positively correlated with Dorea, and Veillonella in 
the T1DM subjects. However, a negative correlation was observed between total folate 
intake with Suttterella, Odoribacter, Rikenellaceae, and Clostridiales. Also, both 
iodine and vitamin E were positively correlated with Faecalibacterium. In regard to 
vitamin D and phosphorus, both were positively correlated with Haemophilus. A 




positive correlation was also observed between biotin and Peptostreptococcaceae; 
lactose and Peptostreptococcaceaeo; and trans fatty acids with Bacteroides. On the 
other hand, SFA was found to be negatively correlated with Sutterella and 
Phascolarctobacterium in the T1DM subjects. Dietary fiber was found to be negatively 
correlated with Alistipes and Ruminococcus.  
Similar to the T1DM group, healthy controls showed a positive correlation with 
vitamin D, but with a different microbial genus, which is Dorea. Unlike the T1DM 
group, healthy controls showed a negative correlation between folic acid and 
Prevotella. Total folate was observed to be negatively correlated with 
Peptostreptococcaceaeo and Clostridiaceae. In addition, in healthy controls, both 
vitamin K and pantothenic acid were found to be negatively correlated with 
Turicibacter and Suttterella, respectively (Figure 18B).  
In regard to the obese group, no network association was observed between 
dietary intake and microbial composition. In the case of T1DM-OB subjects, SFA was 
found to be positively correlated with Coprococcus and Dialister and negatively 
correlated with Bacteroides. Unlike T1DM patients, a positive correlation was 
observed between total folate level and Lachnospira. Also, pantothenic acid showed a 
positive correlation with Lanchnospiraceae and a negative correlation with 
Parabacteroids. In T1DM-OB, Suttterella was only observed to be negatively 


















































Figure 18. Network analysis between gut microbiome and dietary factors. A: 
correlation observed between microbial genus and diet in T1DM subjects. B: 
correlation observed between microbial genus and diet in healthy controls. C: 
correlation observed between microbial genus and diet in T1DM-OB subjects. Note: 




4.1.8 Correlation between SCFAs and gut microbiome using network analysis  
 
Network analysis was also conducted to determine the possible  correlation of gut 
microbiome with SCFAs for the four study groups. The butanoic acid was found to be 
positively correlated with the genus Lachnospira and Sutterella in the T1DM subjects 
(Figure 19A). In addition, positive correlation was found between pentanoic acid with  
Sutterella and Bamesiellaceae. However, in the healthy controls, butanoic acid and 





Odoribacter (Figure 19B). Similar to the T1DM group, T1DM-OB subjects showed a 
positive correlation with pentanoic acid, but with different microbial genus, which are 
Blautia and Erysipelotrichaceae (Figure 19C). Unlike T1DM,  Sutterella showed a 
negative correlation with propionic acid in the T1DM-OB group. In addition, 2-
methylbutanoic acid was found to be positively and negatively correlated with 
Ruminococcaceae and Bacteroides respectively. However, in the obese group, 2-








































































Figure 19. Network analysis between gut microbiome and SCFAs. A: correlation 
observed between microbial genus and SCFAs in T1DM subjects. B: correlation 
observed between microbial genus and SCFAs in healthy controls. C: correlation 
observed between microbial genus and SCFAs in T1DM-OB subjects. D: correlation 
observed between microbial genus and SCFAs in obese. Note: blue line indicates 
positive correlation, red line indicates negative correlation 
 
4.2  Discussion  
T1DM is a disease of childhood, affecting mainly children and adolescence [14] 
with an increasing incident rate worldwide [17]. The exact pathophysiology of the 
disease is complex and has been associated with the interaction of multiple factors, 
mainly genetics. However environmental factors, such as diet and infections can 
contribute to affecting the epigenetic modifications and the gut microbiome 
composition [5]. In this study, we aimed to identify the different diet intake and 
differentially methylated genes present in T1DM patients compared to healthy children. 





methylation, and gut microbiome in the development of pediatric T1DM. Up to our 
knowledge, this study is considered the first study to identify differentially methylated 
genes in T1DM children in Qatar and to show a possible correlation with dietary habits 
and gut microbial profiles in the development of the disease.  
Based on the clinical data analysis, a significant increase in blood pressure was 
observed in obese and T1DM-OB subjects compared to the T1DM group (Figure 3). 
Similarly, a study conducted by Parker and colleagues found that obese children and 
adolescents have high blood pressure and an increased risk of developing hypertension 
later in life compared with children with a low BMI [127]. Moreover, a systematic 
review analysis showed that the presence of overweight or obese phenotype during 
childhood is positively correlated with an increased risk of developing hypertension in 
adulthood [128]. Adipose tissue dysfunction and the imbalance between pro/anti-
inflammatory activities of adipocytes observed in obesity are what contribute to high 
blood pressure and elevated risk of hypertension [129]. In addition, from the lipid panel 
tests, only LDL levels were significant between the four study groups, in which it was 
significantly elevated in T1DM-OB compared to obese and T1DM subjects (Figure 4). 
Various studies have shown that obese T1DM children have elevated levels of LDL 
along with high blood pressure, increasing their risk of developing hypertension and 
cardiovascular diseases [130, 131]. Therefore, indicating the possible involvement of 
obesity in modulating the risk of obese children with or without T1DM to develop 
hypertension and other cardiovascular morbidities. 
In this study, we have also observed a significant elevation in the levels of  TSH 
in T1DM-OB and obese subjects when using the Kruskal-Wallis test (Figure 4). 




to the differences in the variability and sample size among the groups. Based on the 
literature, elevated levels of TSH is common among obese children and could result as 
a consequence of obesity since those patients have a low incidence of developing 
thyroid autoantibodies [132]. Regarding the liver function test panel, both AST and 
ALT levels were found to be significantly decreased in our T1DM children in 
comparison to obese and healthy subjects (Figure 4). A possible explanation for the 
increased ALT levels in our healthy controls could be due to their high dietary intake 
of SFA as 75% of them consume a western-like diet with a total SFA % intake being 
14.6 % ( >10% of the recommended). Various published data have shown that high 
intake of SFA induces liver fat content and liver enzymes [133, 134]. In regard to the 
elevated AST levels observed in our obese children, it aligns with the data from the 
literature. A recent study conducted by Pirimoglu and colleagues showed that obese 
and overweight children have elevated levels of both ALT and AST and it is positively 
correlated with liver fat fraction [135]. Another study showed that measurements of 
ALT/AST ratio along with family history could be characteristic biomarkers for the 
development of diabetes in obese Japanese children [136].  
Furthermore, another possible explanation for the significant elevation observed 
in the clinical findings of our patients is due to the fact that they are in the growth and 
developmental stage of becoming young adolescence, which is associated with elevated 
levels of thyroid related hormones and liver related parameters. For example, several 
studies have showed that puberty could induce changes in thyroid hormone levels, and 
be  markedly different between children and  young adults [137, 138]. Similar to thyroid 
levels, liver function tests (AST and  ALT) were also found to be affected by growth 




In the dietary analysis, we have observed a significant decrease in the intake of 
SFA and vitamin-K in the T1DM subjects compared to the control groups (Table 6; 
Figure 5). Based on different studies, the high intake of SFA is found to be positively 
correlated with advanced ß-cell autoimmunity, insulin resistance, and obesity in 
children [46, 140]. In this study, the % intake of SFA in the T1DM group is 9.7%, 
which is considered close to the recommended intake of SFA (10% of the total Kcal 
intake) [126]. Unlike our T1DM subjects, different studies have shown that T1DM 
patients don’t follow the recommended SFA dietary guidelines. For example, studies 
conducted in Australia, Norway, and US showed that the majority of T1DM children 
have significant overconsumption of SFA [141-143]. However, the significant decrease 
seen in the intake of SFA in our T1DM group could be possibly due to the fact that the 
T1DM patients follow medical recommendations and the healthy controls don’t have a 
healthy lifestyle as 75% of them consume a western-like diet with a high SFA intake 
being 14.6 % , thus explaining their elevated ALT levels (Table 7).  
Various studies have shown the important role of vitamin-K in glycemic 
regulation and insulin sensitivity. It is suggested that vitamin-K intake is associated 
with improved glucose levels as higher intake was correlated with higher insulin 
sensitivity and better glycemic control [144]. In a T1DM rat model, administration of 
vitamin-K prevented the development of hyperglycemia and cancellous osteopenia 
[145]. Another study showed the same conclusion, where T1DM rats treated with 
vitamin-K have improved insulin secretion and normal levels of glucose and HbA1c 
[146]. Therefore, it is recommended that T1DM patients have a diet rich in vitamin-K.  
Moreover, a significant higher intake of pantothenic acid was observed in 




multi-comparison analysis showed no significance among the single groups, which 
could be due to the differences in sample size and the variability between the groups. 
Pantothenic acid (vitamin B5) is known to be involved in fatty acid metabolism, 
especially in the citric acid cycle [147]. In a diabetic rat model, pantothenic acid ( 
Dexpanthenol ) was found to restore endothelial function and reduce glucose levels 
[148]. The role and involvement of pantothenic acid in T1DM is not clearly understood, 
thus further studies are needed to understand its beneficial effect.  
Various studies have been published that show the involvement and association 
of DNA methylation in the development of T1DM [7, 8, 87, 149]. In regard to our DNA 
methylation analysis, we have identified Suppressor APC domain containing 1   
SAPCD1 to be hypermethylated inT1DM children when compared to healthy controls 
(Table 7). We have also identified DnaJ heat shock protein family (HSP40) member 
C7 (DNAJC7) to be differentially methylated and hypomethylated in T1DM-OB 
patients compared to the obese group (Table 7). SAPCD1 gene is known to be involved 
in the establishment of mitotic spindle orientation and the negative regulation of protein 
localization to the cell cortex. Based on the literature, there is no published data that 
correlate this gene with T1DM disease. However, there are studies that showed its 
correlation with different types of cancer, such as breast, lung, and familial papillary 
thyroid cancer [150-152]. The link between cancer and diabetes has long been 
investigated as diabetic patients have an increased risk of developing specific types of 
cancer, such as liver, kidney, and pancreatic cancer [153]. The link between T1DM and 
cancer is not well understood as most studies presented in the literature discuss the link 
between T2DM with cancer due to its increased prevalence compared to T1DM [154]. 




and cancer as it contributes to oncogenesis, tumor cell resistance, and cell death 
inhibition [155, 156]. A recent genome-wide association study done by Hebbar et al. 
(2020) found a significant association between high fasting plasma glucose levels and 
the Valyl-TRNA Synthetase gene (VRAS )[157]. In addition, when they performed 
genotype tissue expression analysis, they found that this gene was involved in the 
regulation of SAPCD1 among other genes [157]. Further studies are needed to 
investigate and understand the involvement and role of the SAPCD1 gene in T1DM 
pathogenesis.  
Although the role of the DNAJC7 gene is not well identified in T1DM 
pathogeneses, various studies investigated its involvement in T2DM and insulin 
resistance. DNAJC7, also known as cytoplasmic constitutive active/androstane receptor 
retention protein (CCRP), belongs to the heat shock protein 40 (HSP40) family [158]. 
Various studies have shown the effect of impaired heat shock response on insulin 
production and ß-cell function, due to dysregulated DNAJC that results in the 
progression of T2DM [159-161]. A study conducted using CCRO knockout mice found 
that the absence of DNAJC7 expression resulted in liver steatosis and abnormal serum 
lipid values, including elevated LDL levels [158]. Based on our analysis, T1DM-OB 
patients were found to have an elevated LDL level, correlating with the data presented 
in the literature.  In addition, pathway analysis revealed a number of pathways and 
molecular functions associated with liver function and lipid metabolism in T1DM-OB 
subjects. Furthermore, IPA analysis showed that gastrointestinal, hepatic and metabolic 
disorders were affected in T1DM-OB patients (Figure 10A), which were all seen in 




Furthermore, disease pathway analysis generated by IPA showed significance 
in reproductive system diseases in both T1DM and T1DM-OB subjects compared to 
controls (Figure 8, 10A). Based on the literature, different studies have shown that 
women with T1DM have menstrual disturbances and lower fertility rates compared to 
healthy controls [166, 167]. Also, hyperglycemia and hyperinsulinemia due to insulin 
deficiency and exogenous insulin injection are found to induce the risk of developing 
hypogonadism, hyperandrogenism, and polycystic ovarian morphology in T1DM 
patients [168].  
Disease pathway analysis also revealed cardiovascular diseases in the 
comparison between T1DM patients and healthy controls (Figure 8). Various studies 
have shown that young T1DM patients have an increased risk of developing 
cardiovascular diseases later in life as the increased risk is associated with the diabetes 
duration [169-171]. Therefore, the diseases identified in this study are considered long-
term morbidities commonly observed at the adult stage of T1DM patients.  
In this study, we were able to identify canonical pathways between T1DM-OB 
and obese subjects, which are aldosterone signaling in epithelial cells, xenobiotic 
metabolism CAR/PXR pathways, and NRF2 mediated oxidative stress respond (Figure 
9). Aldosterone overproduction is usually observed in T1DM patients with diabetic 
nephropathy due to impaired regulation of the renin-angiotensin-aldosterone system 
(RAAS) [172]. In a T1DM rat model, blockage of Aldosterone signaling in epithelial 
cells was observed to increase the expression of tight junction proteins, thus regulating 
the permeability of solutes across the epithelial membrane [173]. In regard to 
xenobiotic metabolism CAR/PXR pathways, which mainly take place in the liver, it 




[174, 175]. A study conducted by Dong and colleagues found that T1DM mice showed 
an increase in the expression of drug-metabolizing cytochrome P450, whereas this 
induction was absent in CAR knockout T1DM-induced mice [174]. Therefore, 
xenobiotic metabolism through CAR receptors has a potential impact on the efficiency 
and toxicity level of different drugs. Moreover, the NRF2 signaling pathway was 
reported to be impaired in T1DM conditions, leading to insufficient protection against 
hypoglycemia-induced oxidative damage in the hippocampus associated with long-
term cognitive abnormalities [176].  
Regarding the gut microbiome composition, previous data from our group 
showed that T1DM patients have a low microbial abundance and richness compared to 
healthy controls (unpublished; Figure 11, supplementary figure S2). In the literature, 
there are conflicting results regarding the diversity and richness of the microbial flora 
in the case of T1DM development. Various human and animal-based studies have 
reported decreased alpha diversity in association with T1DM development [177, 178]. 
However, it was also reported that gut microbial diversity and richness are increased in 
T1DM patients compared to healthy controls [78].  
 In addition to its influence on the immune system, the gut microbial 
composition may have also an influence on different epigenetic modifications, 
including DNA methylation in the development of T1DM. The gut microbiome can 
affect DNA methylation pattern through the production of the epigenetically active 
metabolite, such as certain vitamins, butyrate, folate, and acetate [179]. In metabolic 
conditions characterized by gut microbial dysbiosis, such as T1DM, altered 
concentrations of these vitamins and cofactors are observed leading to aberrant DNA 




Besides, a study conducted by Ghadimi et al. found that probiotic bacteria, such as 
Bifidobacterium breve and Lactobacillus rhamnosus downregulate the expression of 
IL-17, IL-23, and CD40 enhancing the DNA methylation through its metabolites and 
inhibiting the NF-kB pathway [183]. Probiotic supplementation (containing 
Bifidobacterium breve Bb12 and L. rhamnosus GG) was also found to affect the DNA 
methylation pattern of obesity-related genes in pregnant women and their children. The 
authors of this study found that in response to probiotic intake a total of 38 and 68 genes 
were differentially methylated in women and their children, respectively [184]. The 
women supplemented with the probiotics showed a decreased methylation level in the 
promoter region of fat mass and obesity-associated (FTO) gene and methionine 
sulfoxide reductase A (MSRA) gene, which are important genes involved in obesity-
related pathways [184].  
Regarding the SCFA analysis in this study, butanoic acid concentration, also 
known as butyric acid, was found to be significantly elevated in T1DM-OB patients 
(Figure 15). However, based on the literature, different studies have shown that young 
children with T1DM have reduced levels of SCFAs, including butyrate [185, 186], 
which contrasts the results obtained in our analysis. A study conducted by Traisaeng 
and colleagues found that upon supplementation of Leuconostoc mesenteroids, 
increased levels of butyric acid were observed [187]. They also found that butyric acid 
was associated with elevated insulin levels and reduced glucose levels in vitro (Min 6 
cell culture) and in vivo (T1DM mice model) [187].  
The gut microbial composition is not the only factor affecting butyric acid 
levels, different dietary factors are found to influence its levels, such as fat and fiber 




pathogen (SFP) rats given a high-fat diet have significantly decreased levels of butyric 
acid when compared to rats given a normal chow diet [188]. A high-fat diet is known 
to be an important risk factor in various inflammatory and metabolic disorders, 
including obesity and diabetes [189]. In contrast, fiber intake was found to be associated 
with an increased level of butyric acid in obese children indicating its potential 
beneficial effect [190]. Besides, It has been found that dietary fiber-mediated 
modulation of the gut microbiome and SCFAs, including butyric acids, protect against 
the development of diabetic nephropathy through the action of GPR109A and GPR43 
[191]. In our study, the T1DM-OB group has 11.6 % intake of SFA, which is slightly 
higher than the recommended intake (10%) [126]. Therefore, the increased level of 
butyric acid observed in our T1DM-OB group could be explained by their nutritional 
intake as they consumed normal to slightly elevated fat intake. Understanding the link 
between different dietary components and butyric acid could provide a better 
understanding of the pathophysiology of T1DM.  
There is also evidence on the epigenetic effect of butyric acid and its possible 
influence on the development of T1DM [192, 193]. In a colitis model, butyrate was 
found to induce the differentiation of T-regulatory cells in colonic epithelium through 
enhancing Histone 3 acetylation in the promoter region of FOX-3 locus [194]. In a 
T1DM mice model, the salt form of butyrate (sodium butyrate) was found to reduce 
glucose levels and increase insulin levels through histone acetylation and inhibition of 
histone deacetylase (HADC) [195]. Further studies are needed to explore the effect of 
butyric acid on other epigenetic modifications, such as DNA methylation and its 




We have also performed network analysis to determine the potential link 
between DNA methylation, nutrition, and gut microbiome in the development of T1DM 
disease in children. In our analysis, an association between diet and detected CpG 
methylation level was only observed with folate and thiamin intake in the healthy 
controls (Figure 16). Folate is known to be involved in the process of DNA methylation 
as it acts as a methyl donor for the synthesis of  S-adenosylmethionine (co-substrate 
required in DNA methylation) [196]. Based on the literature, folate intake was 
associated with beneficial effects on glucose homeostasis by acting as an epigenetic 
modulator. Studies have shown that folate supplementation is associated with 
methylation levels of CAMKK2 and adipose-related genes, thus regulating pancreatic 
functions and insulin secretion [116, 197]. In addition, specific gut microbiome, such 
as Bifidobacterium, and Enterococcus, are known as a source of folate biosynthesis in 
the distal intestine [198]. In our analysis, healthy subjects had the highest intake of 
folate (an average of 141.6 mcg) compared to the other study groups, which could 
explain why an association with DNA methylation level was only observed in the 
healthy controls.  
In this study, we have also observed a negative correlation between DNA 
methylation level and Faecalibacterium in T1DM subjects (Figure 17 A). ). T1DM 
patients have the highest relative abundance of Faecalibacterium accounting for an 
average of 6.25% compared to the other study group.  Faecalibacterium is an anti-
inflammatory bacteria from the phylum Firmicutes involved in improving intestinal 
membrane integrity through the production of butyrate [199]. Different studies have 
reported the decrease in Faecalibacterium abundance in T1DM children associated 




discuss the link between Faecalibacterium and DNA methylation in T1DM. However, 
since Faecalibacterium is a butyrate producer, it can act as an epigenetic modulator 
through the production of butyrate [194, 195]. In the obese group, a positive correlation 
was observed between DNA methylation and Lachnospira (Figure 17 C). According to 
the literature, Lachnospira is a gut microbial marker observed in obesity-related 
conditions [202]. Although no network association was identified between diet and gut 
microbiome in obese groups, in the T1DM-OB, Lachnospira showed a positive 
association with folate level, which is an epigenetic modulator (Figure 18C). This 
discrepancy in the network analysis could be attributed to the small sample size. More 
studies are needed to further understand the link between DNA methylation, folate 
intake, and Lachnospira as it could explain possible association between DNA 
methylation, nutrition and microbiome in the development of disease.  
In the network analysis between diet and microbiota, we identified a negative 
correlation of the SFA with Sutterella and Phascolarctobacterium in T1DM subjects 
(Figure 16). According to the literature, Phascolarctobacterium was previously 
reported to be positively correlated with SFA intake in obesity [203]. In the case of 
Sutterella, no study reported its possible correlation with SFA intake. However, high 
levels of Sutterella were found to be associated with extra virgin olive oil (EVOO), 
which is characterized by high levels of Monounsaturated Fatty Acids (MUFA) and 
low levels of SFA [203, 204]. In this study, T1DM patients report a low intake of SFA, 
and the Sutterella relative abundance was 1.03%, which is lower in comparison to 
healthy subjects (2.04%) even if it didn’t reach statistical significance (Appendix C, 




In regard to the SCFAs and microbiome network analysis, Sutterella was also 
observed to be positively correlated with butanoic acid and pentanoic acid in T1DM 
patients (Figure 16). Based on the literature, Sutterella was found to be significantly 
increased in T1DM patients compared to controls [72]. Another study reported the same 
finding with high levels of Sutterella being observed in T1DM along with the impaired 
activity of IL-17 secretion [205]. Sutterella from the phylum Proteobacteria is 
considered a pro-inflammatory agent and has been frequently involved in different 
inflammatory and metabolic disorders, such as inflammatory bowel disease (IBD), and 
autism [206]. No study reported the possible correlation between Sutterella and SCFA 
production in T1DM. However, it has been found that subjects with overconsumption 
of alcohol have elevated abundance of Sutterella compared to controls, but no 
significant correlation was observed with SCFAs level [207].  
There are several limitations associated with this study, mainly the small size of 
the study subjects, particularly for the healthy controls, the T1DM obese and the obese 
groups. Another limitation is in the use of 24-hour dietary recall, which records one day 
intake and it may not be a good representative of the patients’ dietary habits. To 
overcome the uncertainties of the dietary records, our recruiting criteria involved a 
narrow range of age (6-12 years) to exclude variability in social and dietary habits 
exhibited by teenagers. Also, correction of blood cell composition wasn’t performed, 
which affects the analysis conducted in this study. Another limitation of this study is 
the absence of gene expression validation to confirm the effect of DNA methylation. 
Larger studies are needed to confirm the findings of this study, involving 




correlation between DNA methylation, diet, and gut microbiome in the pathogenesis of 
T1DM. 
4.3 Conclusion: 
The risk of developing T1DM is increasing worldwide, especially in 
westernized countries. The exact pathophysiology of the disease is complex and 
involves the interaction of different genetic, epigenetic, and environmental factors. The 
interplay between DNA-methylation, diet, and gut microbiome and how this link 
contributes to the pathogenesis of T1DM is yet to be identified. In this study, we were 
able to determine the differentially methylated genes seen in T1DM patients in 
comparison to the T1DM obese, pure obese, and lean controls along with the significant 
functional pathways involved. Both SAPCD1 and DNAJC7 genes were found to be 
possibly implicated in T1DM disease. A possible link was identified between folate 
intake and DNA methylation as well as with microbial genus Lachnospira. In addition 
to the negative association between  Faecalibacterium and DNA methylation in T1DM 
patients. Therefore, the conducted network analysis showed a possible interplay 
between diet, DNA-methylation and gut microbiome and its influence on the 
development of T1DM. More studies are needed to provide further information and 
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Figure S2. CpG DNA methylation levels within study groups. Raw methylation 
data generated from the Illumina Infinium array were imported to the genome studio 




























































































































































































































































































































































































































































Table S1. Differentially methylated unadjusted genes 
 





































Figure S3. Network analysis between CpG methylation level and HbA1c (A) and 
diabetes duration in T1DM-OB subjects. Note: blue line indicates a positive 





































































Figure S4. Relative abundance of gut microbial composition at both the phylum 
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